Kim J, Kim H, Kim W, Lee E, Kim S, Kim T
Signal Transduct Target Ther. 2025; 10(1):15.
PMID: 39828766
PMC: 11743776.
DOI: 10.1038/s41392-024-02106-6.
Tang Q, Wang S, Li H, Liu J, Hu X, Zhao D
Aging (Albany NY). 2024; 16(1):593-616.
PMID: 38206300
PMC: 10817404.
DOI: 10.18632/aging.205398.
Kim J, Park S, Kwak C, Lee Y, Song D, Jung J
Cancer Commun (Lond). 2023; 44(1):47-75.
PMID: 38133457
PMC: 10794009.
DOI: 10.1002/cac2.12510.
Pinanga Y, Lee H, Shin E, Lee H, Pyo K, Kim J
iScience. 2023; 26(9):107625.
PMID: 37670786
PMC: 10475478.
DOI: 10.1016/j.isci.2023.107625.
Rahim N, Wu Y, Sim M, Velaga A, Bonam S, Gopinath S
Pharmaceuticals (Basel). 2023; 16(1).
PMID: 36678607
PMC: 9867095.
DOI: 10.3390/ph16010110.
Systemic TM4SF5 overexpression in Apc mice promotes hepatic portal hypertension associated with fibrosis.
Lee J, Kim E, Kang M, Ryu J, Kim J, Shin E
BMB Rep. 2022; 55(12):609-614.
PMID: 36104259
PMC: 9813423.
Liver-originated small extracellular vesicles with TM4SF5 target brown adipose tissue for homeostatic glucose clearance.
Jung J, Kim J, Kim E, Lee H, Lee H, Shin E
J Extracell Vesicles. 2022; 11(9):e12262.
PMID: 36063136
PMC: 9443943.
DOI: 10.1002/jev2.12262.
TM4SF5-Mediated Regulation of Hepatocyte Transporters during Metabolic Liver Diseases.
Kim J, Kim E, Lee J
Int J Mol Sci. 2022; 23(15).
PMID: 35955521
PMC: 9369364.
DOI: 10.3390/ijms23158387.
Therapeutic effects of TM4SF5-targeting chimeric and humanized monoclonal antibodies in hepatocellular and colon cancer models.
Ko D, Kim E, Shin E, Nam S, Yoon J, Lee J
Mol Ther Oncolytics. 2022; 24:452-466.
PMID: 35211652
PMC: 8841960.
DOI: 10.1016/j.omto.2022.01.006.
Crosstalk between TM4SF5 and GLUT8 regulates fructose metabolism in hepatic steatosis.
Lee H, Kim E, Shin E, Shon J, Sun H, Kim J
Mol Metab. 2022; 58:101451.
PMID: 35123128
PMC: 8866669.
DOI: 10.1016/j.molmet.2022.101451.
TM4SF5-mediated liver malignancy involves NK cell exhaustion-like phenotypes.
Sun H, Kim E, Ryu J, Lee H, Shin E, Lee M
Cell Mol Life Sci. 2021; 79(1):49.
PMID: 34921636
PMC: 8739317.
DOI: 10.1007/s00018-021-04051-x.
Gene Signatures of NEUROGENIN3+ Endocrine Progenitor Cells in the Human Pancreas.
Yong H, Xie G, Liu C, Wang W, Naji A, Irianto J
Front Endocrinol (Lausanne). 2021; 12:736286.
PMID: 34566896
PMC: 8456125.
DOI: 10.3389/fendo.2021.736286.
N-terminus-independent activation of c-Src via binding to a tetraspan(in) TM4SF5 in hepatocellular carcinoma is abolished by the TM4SF5 C-terminal peptide application.
Song H, Lee Y, Kim E, Cho C, Jung O, Lee D
Theranostics. 2021; 11(16):8092-8111.
PMID: 34335982
PMC: 8315060.
DOI: 10.7150/thno.58739.
Role of Transmembrane 4 L Six Family 1 in the Development and Progression of Cancer.
Fu F, Yang X, Zheng M, Zhao Q, Zhang K, Li Z
Front Mol Biosci. 2020; 7:202.
PMID: 33015133
PMC: 7461813.
DOI: 10.3389/fmolb.2020.00202.
The long non-coding RNA SNHG1 promotes bladder cancer progression by interacting with miR-143-3p and EZH2.
Xiang W, Lyu L, Huang T, Zheng F, Yuan J, Zhang C
J Cell Mol Med. 2020; 24(20):11858-11873.
PMID: 32885590
PMC: 7578868.
DOI: 10.1111/jcmm.15806.
Amino acid transporters as tetraspanin TM4SF5 binding partners.
Jung J, Kim J, Kim E, Lee J
Exp Mol Med. 2020; 52(1):7-14.
PMID: 31956272
PMC: 7000776.
DOI: 10.1038/s12276-019-0363-7.
Targeting TM4SF5 with anti-TM4SF5 monoclonal antibody suppresses the growth and motility of human pancreatic cancer cells.
Park S, Kim D, Park J, Kwon H, Lee Y
Oncol Lett. 2020; 19(1):641-650.
PMID: 31897180
PMC: 6924189.
DOI: 10.3892/ol.2019.11134.
TM4SF5-mediated CD44v8-10 splicing variant promotes survival of type II alveolar epithelial cells during idiopathic pulmonary fibrosis.
Kim J, Kim H, Jung J, Song D, Park D, Lee H
Cell Death Dis. 2019; 10(9):645.
PMID: 31501417
PMC: 6733838.
DOI: 10.1038/s41419-019-1878-5.
Clinicopathological significance of TM4SF5 expression in human hepatocellular carcinoma tissues.
Xu B, Lv W, Li X, Zhang L, Lin J
Oncol Lett. 2019; 17(6):5187-5192.
PMID: 31186734
PMC: 6507443.
DOI: 10.3892/ol.2019.10210.
Tetraspanin 1 as a mediator of fibrosis inhibits EMT process and Smad2/3 and beta-catenin pathway in human pulmonary fibrosis.
Liu G, Wang Y, Yang L, Zou B, Gao S, Song Z
J Cell Mol Med. 2019; 23(5):3583-3596.
PMID: 30869194
PMC: 6484435.
DOI: 10.1111/jcmm.14258.